Inhalation Plastics, Inc. v. Medex Cardio-Pulmonary, Inc.

383 F. App'x 517
CourtCourt of Appeals for the Sixth Circuit
DecidedJune 29, 2010
Docket08-4550
StatusUnpublished
Cited by6 cases

This text of 383 F. App'x 517 (Inhalation Plastics, Inc. v. Medex Cardio-Pulmonary, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Inhalation Plastics, Inc. v. Medex Cardio-Pulmonary, Inc., 383 F. App'x 517 (6th Cir. 2010).

Opinion

*518 OPINION

MeKEAGUE, Circuit Judge.

In this appeal, we are called upon to interpret the scope of an alternative dispute resolution clause. Inhalation Plastics, Inc. (“IPI”), a manufacturer and dis-tributer of medical products, filed suit against Medex Cardio-Pulmonary, Inc. (“Medex”) in connection with Medex’s acquisition of IPI and the IPI line of products. In response to the suit, Medex sought to compel arbitration on a portion of IPI’s complaint, which Medex claimed was governed by an alternative dispute resolution clause found within one of the parties’ agreements. The district court determined that none of IPI’s complaint fell within the scope of the clause, and it therefore denied Medex’s request in its entirety. Medex filed this interlocutory appeal, challenging the district court’s determination. After carefully considering the scope of the alternative dispute resolution clause as well as the nature of IPI’s complaint, we have determined that the amount of any damages claimed by IPI falls within the clause’s mandates. We therefore AFFIRM in part and REVERSE in part.

I.

The origins of this dispute date back to 2002 when Medex acquired IPI’s business of manufacturing and distributing medical products. To consummate the deal, the parties executed a series of agreements. One such agreement, titled the Machinery Equipment and Production Lease (“Production Lease”), called for Medex to lease IPI’s machinery and equipment used to manufacture and distribute IPI’s products. As part of the Production Lease, Medex was required to make periodic lease payments to IPI. These “Production Lease Payments” formed part of the consideration paid by Medex for the acquisition of IPI. The full consideration was detailed in the Asset Purchase Agreement (“APA”), which expressly incorporated by reference all of the terms of the Production Lease. Production Lease Payments were based in part on how well IPI’s businesses performed under Medex. Both the APA and the Production Lease contained anti-assignment provisions, limiting either party’s ability to assign its rights or obligations under the agreements.

In December 2004, Medex’s parent corporation, Medvest Holdings Corporation, entered into a separate transaction with Smiths Medical Holdco Limited (“Smiths Holdco”), whereby Medvest Holdings was acquired by Smiths Holdco through a merger. As part of the merger, IPI alleges that Medex assigned all of its rights and obligations under its agreements with IPI to Smiths Medical ASD, a business unit of Smiths Holdco. IPI took the position that this deal violated the anti-assignment provisions of its agreements with Medex. IPI informed Medex of its belief, and the two sides worked to negotiate a mutually agreeable outcome. According to IPI, these negotiations resulted in an oral promise from Medex’s president that Me-dex would buy IPI out of the agreements in exchange for IPI not interfering with the Medex-Smiths Holdco deal. IPI claimed that its president accepted this offer, though Medex never followed through with its end of the agreement.

The parties continued to work towards a mutually agreeable resolution. However, they ultimately failed to reach an agreement, and IPI filed a diversity suit in federal district court against Medex for breach of the written agreements, which were part of Medex’s original acquisition of IPI, and breach of the subsequent oral promise from Medex’s president that Me-dex would buy IPI out of the agreements. In its federal complaint, IPI contended *519 that it was harmed by Medex’s improper assignment to Smiths Medical because Me-dex ceased operation of IPI’s product line as a result of the assignment, which negatively impacted the Production Lease Payments that IPI was supposed to receive. Pursuant to a motion filed by Medex, the district court dismissed the claim for breach of the written contracts because it found that the oral agreement necessarily superseded the written-contracts. Inhalation Plastics, Inc. v. Medex Cardio-Pulmonary, Inc., 2:07-cv-116 at 8, 2007 WL 4270621 (S.D.Ohio Dec. 3, 2007).

IPI then filed an amended complaint, claiming that Medex breached the oral contract or, in the alternative, that Medex breached the written agreements. Count II of this amended complaint alleged that Medex breached various portions of the written agreements. All of these allegations are contained under the single heading “Count II — Breach of Written Contract.” While the exact nature of IPI’s allegations are difficult to ascertain from the pleadings, all of the following are alleged in some form in Count II: breach of the anti-assignment provisions for the assignment to Smiths Medical; breach of the Production Lease for losing and moving the machinery; breach of the APA for failing to provide IPI with required reports and access to books and records; and breach of the Production Lease for improper calculation of Production Lease Payments.

In response to IPI’s amended complaint, Medex filed a motion to dismiss or stay and compel binding dispute resolution on Count II. Medex based its motion on Section 2.1.3 of the APA, titled “Audit of Production Lease Payments,” which reads in relevant part:

In the event that [Medex] and [IPI] are unable to agree on the amount due for any Production Lease Payment to be paid hereunder, [Medex] shall pay to [IPI] that portion of the respective Production Lease Payment that is not in dispute, and only that portion of any amount alleged to be owed by [Medex] to [IPI] shall be submitted for final resolution to the Columbus, Ohio office of PriceWaterhouseCoopers, LLP (the “Independent Accountants”); provided, however, that in the event that Price-WaterhouseCoopers, LLP, acts at any time in the future as the independent auditors for [Medex] or any affiliate of [Medex], then another “big five” accounting firm (to be mutually agreed upon by the parties hereto) shall act as the Independent Accountants. The Independent Accountants shall make such final determination on the basis of such procedures as the Independent Accountants, in their sole judgment, deem applicable and appropriate, taking into account the nature of the issue, the amount(s) in dispute and the respective positions asserted by the parties. The Independent Accountants shall review the disputed matters and as promptly as practicable deliver to [IPI] and [Medex] a statement in writing setting forth their determination as to the disputed amount. Such determination shall be final and binding upon the parties without further right of appeal.

This language is buried within the middle of Section 2.1.3, which consists of one single-spaced paragraph spanning over a page in length. Aside from the above-quoted language, Section 2.1.3 also gives IPI the right to review, audit, and examine Medex’s books and records that contain information related to the Production Lease Payments. Both the APA and the Production Lease contain other clauses that speak to dispute resolution. Specifically, the APA contains a governing-law clause (stating that Ohio state law governs) and a cumulative-remedies clause. *520 In acldition, the Production Lease contains a remedies clause, a waiver-of-jury clause, and a governing-law clause.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
383 F. App'x 517, Counsel Stack Legal Research, https://law.counselstack.com/opinion/inhalation-plastics-inc-v-medex-cardio-pulmonary-inc-ca6-2010.